Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant in MDD and Insomnia
NCT07555743Phase 4Not yet recruiting
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Insomnia comparing Daridorexant 50mg with Placebo (2 arms). Primary endpoint: Insomnia Severity Index at 3 months. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
daridorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT07555743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07555743.